Skip to main content

Table 2 Results of the analysis of cases with or without overall nausea among 312 cases receiving palonosetron

From: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

 

Cases with nausea

Cases without nausea

p value

Case number

66 (21.2%)

246 (78.8%)

 

Age, mean ± SD

60.4 ± 12.6

65.2 ± 10.2

< 0.001

≥75 years, n (%)

5 (7.6)

42 (17.1)

0.05

≥70 years, n (%)

19 (28.8)

91 (37.0)

0.21

Sex, n (%)

28:38

120:126

0.35

(42.4:57.6)

(48.8:51.2)

PS 0:1 + 2, n (%)

26:40

129:117

0.05

(39.4:60.6)

(52.4:47.6)

Aprepitant, n (%)

50 (75.8)

165 (67.0)

0.17

Neut < 1000, n (%)

5 (7.6)

18 (7.3)

0.63

Hb < 10 mg/dl, n (%)

32 (48.5)

142 (57.7)

0.18

CRE ≥1.1 mg/dl, n (%)

7 (6,5)

7 (2.8)

0.07

ALT > 2.5 ULN, n (%)

17 (25.8)

38 (15.9)

0.05

Constipation, n (%)

28 (42.4)

70 (31.8)

0.03

Diarrhea, n (%)

19 (28.8)

48 (19.0)

0.10

Oral mucositis, n (%)

20 (30.3)

57 (20.8)

0.23

Neuropathy, n (%)

47 (71.2)

139 (53.6)

0.03

General fatigue, n (%)

49 (74.2)

113 (44.3)

< 0.001

Pain NRS ≥1, n (%)

22 (33.3)

69 (31.5)

0.40

L-OHP, n (%)

42 (63.6)

136 (55.3)

0.22

CPT-11, n (%)

8 (12.1)

52 (21.1)

0.09

CBDCA, n (%)

16 (24.2)

58 (23.6)

0.91

Oral intake of 5-FU, n (%)

39 (59.1)

116 (47.2)

0.08

  1. PS performance status, NEUT neutrophil, ULN upper limit of normal, NRS numerical rating score, L-OHP oxaliplatin, CPT-11 irinotecan, CBDCA carboplatin, SD standard deviation
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us